In the preclinical stage, paclitaxel and Momelotinib (ATP-competitive inhibitor of JAK1/2, previously named CYT387) inhibited JAK2/STAT3 activation, reduced tumor burden, abrogated cancer stem cell expressions and prolonged disease-free survival in a murine xenograft model [89,150]. Here, JAK2 is linked to neoplasm.